All the news

The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load and improved liver enzyme levels in real-world studies in France and Austria, according to findings presented ...

Limiting re-infection with hepatitis C in people who use drugs is most likely to be achieved by intensifying provision of sterile injecting equipment for people using needle and syringe programmes and increasing ...

Unstable housing may be responsible for up to one in five new infections with HIV or hepatitis C among people who inject drugs in the United Kingdom and the United States, a ...

People with both HIV and hepatitis B have a higher rate of non-liver cancers compared to other people with HIV, a large European study has found. The study investigators, who have published ...

Some people with liver cirrhosis remain at risk for developing hepatocellular carcinoma (HCC) even after hepatitis C treatment, according to study results presented at The Liver Meeting. Not achieving a cure was the biggest ...

Providing hepatitis B treatment for everyone who needs it in Malawi is an achievable public health goal, researchers from the Malawi-Liverpool-Wellcome Trust programme report, following community surveys in Blantyre, Malawi. Hepatitis B treatment ...

Access to direct-acting antivirals to cure hepatitis C has slashed incidence rates for groups most affected in Australia. Among gay and bisexual men living with HIV, incidence fell by 78% ...

People who have experienced failure of multiple courses of direct-acting antiviral treatment can be cured of hepatitis C with a combination of three direct-acting antivirals plus ribavirin, a review of heavily treatment-experienced patients ...